Chief of the Pathogenesis and Basic Research Branch of the NIAID Division of AIDS
National Institute of Allergy and Infectious Diseases (NIAID)
USA
Karl Salzwedel is Chief of the Pathogenesis and Basic Research Branch of the NIAID Division of AIDS. He oversees a broad portfolio of grant funding, including the Martin Delaney Collaboratories for HIV Cure Research, the Centers for AIDS Research (CFAR), the Centers for HIV Structural Biology and the NIH HIV Reagent Program. Karl also supports the CFAR Africure programme and the U.S. Military HIV Research Program’s DELIVER initiative to expand HIV cure research capacity. He is an organizer of the NIAID Strategies for an HIV Cure scientific meeting and the HIV Persistence During Therapy international workshop. Prior to joining NIAID, Karl was Senior Director of Virology and Drug Discovery at Panacos Pharmaceuticals, Inc., where he led efforts to characterize the first-in-class HIV maturation inhibitor, bevirimat. He received his postdoctoral training at NIAID, his PhD from the University of Alabama at Birmingham and his Bachelor’s degree from the University of North Carolina at Chapel Hill.